The Aquaculture Vaccines Market Size is valued at USD 477.1 Million in 2023 and is predicted to reach 1003.7 Million by the year 2034 at a 7.5% CAGR during the forecast period for 2024-2034.
Vaccination creates or enhances immunity against a particular illness or group of illnesses. There is always a possibility of pathogenic outbreaks in aquaculture methods, impacting the farm's output. Vaccines for aquaculture are used to shield the fish from any infection. Increased demand for food products made from aquatic animals, such as oil, protein powders, caviar, and meat, as well as the rate of disease progression in marine animals, would restrain the growth of the aquaculture vaccines market. Over the forecast period, there is expected to be a rise in demand for commercial aquaculture vaccines due to the increased prevalence of bacterial diseases among aquatic species. The aquaculture vaccine market has also expanded due to rising global demand for and production of aquatic species.
However, the aquaculture vaccinations business has suffered due to the COVID-19 epidemic. Additionally, it's anticipated that short-term market weakness would result from growing knowledge of the risks associated with animal-to-human virus transmission. Moreover, complicated vaccine production processes, high vaccination costs, and strict regulatory requirements for aquaculture vaccine approval would restrain the market's expansion.
The Aquaculture Vaccines market is segmented on the vaccine type, application, route of administration and species. Based on the vaccine type, the market is segmented into Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine and Others. Based on application, the Aquaculture Vaccines are segmented into Bacterial Infection, Viral Infections, Combined Bacterial and Viral Infections and Others. Based on route of administration, the market is segmented into Immersion Vaccines, Injection Vaccines and Oral Vaccines. Based on species, the market is segmented into Salmon, Seabass and Seabream, Tilapia, Trout, Turbo and Carp.
Inactivated vaccines dominated the market for vaccinations used in aquaculture. Large quantities of the disease-causing microorganisms are fermented to create inactivated bacterial and viral vaccines. Then, inactivating chemicals like formalin are used to eliminate all the germs. These inactivated organisms have their basic structure, original antigen properties, and form, which causes an immune response. The recombinant vaccines market is projected to expand significantly. Recombinant vaccines can imitate naturally occurring illnesses and induce a potent immune response in inoculated fish. Recombinant vaccines are also simpler to manufacture on a large-scale, commercial basis.
Injection vaccines dominated the market share for aquaculture vaccines. Injection vaccinations allow for the direct induction of a systemic immune response by delivering antigens directly into a bodily cavity or muscle. Injection vaccines' superior capacity to cure various bacterial and viral infectious diseases compared to other routes of administration is thus expected to boost industry statistics.
The European Aquaculture Vaccines market is expected to register the highest market share in revenue in the near future. The main drivers propelling this regional market include Norway's position as the region's largest salmon exporter, supportive government and business sector initiatives, growing public concern about the prevalence of antibiotic resistance, and the existence of significant companies. The Norwegian Medicines Agency has specific guidelines and recommendations for autogenous vaccination applications. Additionally, autogenous vaccinations should only be used when commercial vaccines are either not accessible or do not provide adequate protection. In addition, Asia Pacific is projected to expand in the global Aquaculture Vaccines market because of growing demand, a thriving aquaculture industry, encouraging government initiatives, adequate water resources in many regions, and a drive toward sustainable aquaculture, among other factors. Several aquatic species, including tilapia, are abundant in this area.
| Report Attribute | Specifications |
| Market size value in 2023 | USD 477.1Million |
| Revenue forecast in 2034 | USD 1003.7 Million |
| Growth rate CAGR | CAGR of 7.5% from 2024 to 2034 |
| Quantitative units | Representation of revenue in US$ Million and CAGR from 2024 to 2034 |
| Historic Year | 2021 to 2023 |
| Forecast Year | 2024-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments covered | Vaccine type, Route of Administration, Species, Application |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
| Competitive Landscape | Pharmaq AS (Zoetis, LLC) (Norway), Merck Animal Health (Merck & Co., Inc.) (USA), KoVax Ltd. (Part of Phibro Animal Health) (Israel), Hipra (Spain), Tecnovax SA (Argentina), Veterquimica S.A. (Chile), Nisseiken Co. Ltd. (Japan), Virbac S.A. (France), Elanco (USA) and Kyoritsuseiyaku Corporation (Japan). |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Vaccine Type-
By Application-
By Route of Administration-
By Species-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.